Expanding Options for Patients With Acute Myeloid Leukemia: Current and Evolving Therapeutic Approaches

The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with AML.

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for medical oncologists, surgical oncologists, pathologists, physician assistants, nurses, pharmacists, and other healthcare professionals who treat patients with AML.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Characterize the pathophysiologic, clinical, cytogenetic, and molecular profiles that guide individualized selective therapies for patients with AML
  • Plan evidence-based therapeutic strategies for older patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
  • Select optimal maintenance treatment following induction therapy for patients who are not candidates for, or who choose not to proceed to, hematopoietic stem cell transplantation
  • Develop personalized treatment plans for therapeutically targetable molecular subsets of AML
  • Discuss with patients the clinical evidence and guideline recommendations on the detection of measurable residual disease (MRD) and the association with a higher relapse rate and worse survival in AML
Additional information

Supported by an independent educational grant from AbbVie Inc.
Supported by an educational grant from Genentech, a member of the Roche Group.
Supported by an independent medical education grant from Jazz Pharmaceuticals.

Course summary
Available credit: 
  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation
Course opens: 
Course expires: 

Naval G. Daver, MD
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Amir T. Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts


NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Naval G. Daver, MD: 
Abbvie, Inc.: Consultant/Advisor/Speaker; Researcher
Agios, Inc.: Consultant/Advisor/Speaker
Amgen Inc.: Consultant/Advisor/Speaker; Researcher
Arog Pharmaceuticals, Inc.: Consultant/Advisor/Speaker
Astellas Pharma US, Inc.: Consultant/Advisor/Speaker; Researcher
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker; Researcher 
Celgene Corporation: Consultant/Advisor/Speaker
Daiichi-Sankyo Co.: Consultant/Advisor/Speaker; Researcher
Fate Therapeutics: Researcher
Genentech, Inc.: Consultant/Advisor/Speaker; Researcher 
Gilead Sciences, Inc.: Consultant/Advisor/Speaker; Researcher
GlycoMimetics, Inc.: Researcher
Hanmi Pharmaceutical Co., Ltd.: Researcher
ImmunoGen, Inc.: Independent Contractor; Researcher
Jazz Pharmaceuticals Inc.: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Consultant/Advisor/Speaker
Novimmune SA: Researcher
Pfizer Inc.: Consultant/Advisor/Speaker; Researcher
Servier Pharmaceuticals LLC: Consultant/Advisor/Speaker
Shattuck Labs, Inc.: Consultant/Advisor/Speaker
Syndax Pharmaceuticals Inc.: Consultant/Advisor/Speaker
Trillium Therapeutics Inc.: Consultant/Advisor/Speaker; Researcher
Trovagene, Inc.: Researcher

Amir T. Fathi, MD
Abbvie, Inc.: Consultant/Advisor/Speaker
Agios, Inc.: Consultant/Advisor/Speaker
Amgen Inc.: Consultant/Advisor/Speaker
Astellas Pharma US, Inc.: Consultant/Advisor/Speaker
Bristol-Myers Squibb Company: Consultant/Advisor/Speaker
Celgene Corporation Consultant/Advisor/Speaker
EnClear Therapies: Consultant/Advisor/Speaker
Foghorn Therapeutics: Consultant/Advisor/Speaker
Forma Therapeutics, Inc.: Consultant/Advisor/Speaker
Genentech, Inc.: Consultant/Advisor/Speaker
ImmunoGen, Inc.: Consultant/Advisor/Speaker
Ipsen: Consultant/Advisor/Speaker
Kite Pharma: Consultant/Advisor/Speaker
Mablytics, Inc.: Consultant/Advisor/Speaker
MorphoSys AG: Consultant/Advisor/Speaker
Novartis Pharmaceuticals Corporation: Consultant/Advisor/Speaker
Orum Therapeutics: Consultant/Advisor/Speaker
Servier Pharmaceuticals LLC: Consultant/Advisor/Speaker
Takeda Pharmaceuticals North America, Inc.: Consultant/Advisor/Speaker

NCCN and CCO Staff Disclosures

None of the planners/managers for this educational activity has relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.5 contact hours.

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-22-098-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until August 26, 2023. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.50 AAPA Category 1 CME credit
  • 1.50 ACPE contact hours
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 ANCC contact hours
  • 1.50 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing